Other Funding Opportunities

Interest in Research to Improve Diagnostic Performance in Ambulatory Care Settings

Release Date: May 17, 2013

Purpose: The mission of the Agency for Healthcare Research and Quality (AHRQ) is to improve the quality, safety, efficiency, and effectiveness of healthcare for all Americans. AHRQ achieves this mission by supporting a broad program of health services research and by working with partners to promote improvements in clinical and health system practices that benefit patients.

This Special Emphasis Notice (SEN) informs the research community that AHRQ intends to support research designed to improve diagnostic performance in ambulatory care settings. With this notice, AHRQ is providing information about one of its highest research priorities for investigator initiated applications. This includes gaining a better understanding of the incidence, cost, determinants, and strategies for preventing or mitigating diagnostic errors (i.e., misdiagnosis, missed diagnosis, delayed diagnosis). For the purposes of this SEN, ambulatory care refers to health care provided in emergency departments; clinicians’ offices and practices, both large and small; outpatient clinics; community health centers; urgent care centers; and ambulatory surgery centers. Researchers from non-ambulatory settings with a strong interest in fostering safe, high quality diagnostic performance are welcome to apply, but must do so in partnership with an ambulatory care organization.

Link: http://grants.nih.gov/grants/guide/notice-files/NOT-HS-13-009.html

 

_____________________________

Molecular and Cellular Analysis Technology Development for Cancer Research funding opportunities are intended to support the development of technologies that are novel and potentially transformative to the molecular and cellular analysis of cancer, which may in turn accelerate basic or clinical cancer research. Applications must offer novel measurement, probing, or targeting of cancer relevant targets at the molecular or cellular level.

  • RFA-CA-15-002 (R21): Supports an early-stage feasibility study (inception through preliminary development) to demonstrate core functional capabilities of the proposed technology.
  • RFA-CA-15-003 (R33): Assumes completion of the initial phase of development and supports the advanced development and robust validation of the technology.

Cancer-relevant Biospecimen Science Technologies funding opportunities are centered on the development and validation of novel technologies to improve or assess the quality of cancer-relevant biospecimens for research or clinical care. Applications must offer novel approaches for procurement, preservation, and/or isolation of proteins, DNA, RNA and other small molecules from biospecimens or otherwise assess their biological integrity. The emphasis is on reducing the impact of pre-analytical variations in the collection, processing, handling, and preservation of cancer-relevant biospecimens or their derivatives to improve their quality and utility for cancer research or clinical care. 

  • RFA-CA-15-004 (R21): Supports an early-stage feasibility study (inception through preliminary development) to demonstrate core functional capabilities of the proposed technology.
  • RFA-CA-15-005 (R33): Assumes completion of the initial phase of development and supports the advanced development and robust validation of the technology.
Notice of NIBIB’s Participation in PAR-15-075 “Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)”
(NOT-EB-15-002)
National Institute of Biomedical Imaging and Bioengineering
  • Innovative Molecular Analysis Technologies for Cancer Research (R21)
    (RFA-CA-15-002)
    National Cancer Institute
    Application Receipt Date(s): March 17, 2015; June 17, 2015; September 22, 2015, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

     

  • Advanced Development and Validation of Emerging Molecular Analysis Technologies for Cancer Research (R33)
    (RFA-CA-15-003)
    National Cancer Institute
    Application Receipt Date(s): March 17, 2015; June 17, 2015; September 22, 2015, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

     

  • Innovative Technologies for Cancer-Relevant Biospecimen Science (R21)
    (RFA-CA-15-004)
    National Cancer Institute
    Application Receipt Date(s): March 17, 2015; June 17, 2015; September 22, 2015, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

     

  • Advanced Development and Validation of Emerging Technologies for Cancer-Relevant Biospecimen Science (R33)
    (RFA-CA-15-005)
    National Cancer Institute
    Application Receipt Date(s): March 17, 2015; June 17, 2015; September 22, 2015, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.